B. Brennan

发表

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma.

B. Coiffier, R. Foà, H. Burger, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment

L. Gibiansky, C. Rayner, R. Robson, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

A grapefruit a day for patients infected with hepatitis C?

P. N. Morcos, Patrick F. Smith, B. Brennan, 2008, Hepatology.

A Pharmacokinetic/Viral Kinetic Model to Evaluate the Treatment Effectiveness of Danoprevir against Chronic HCV

A. Perelson, A. Chatterjee, J. Guedj, 2014, Antiviral therapy.

Safety, Tolerability, and Pharmacokinetics of Ribavirin in Hepatitis C Virus-Infected Patients with Various Degrees of Renal Impairment

J. Grippo, K. Nieforth, P. Martin, 2013, Antimicrobial Agents and Chemotherapy.

Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs

P. N. Morcos, F. Mercier, Li Yu, 2020, Cancer Chemotherapy and Pharmacology.

Safety, Tolerability, and Pharmacokinetics of Intravenous Oseltamivir: Single- and Multiple-Dose Phase I Studies with Healthy Volunteers

C. Chappey, C. Rayner, S. Lennon-Chrimes, 2012, Antimicrobial Agents and Chemotherapy.

Effect of peginterferon alfa‐2a (40KD) on cytochrome P450 isoenzyme activity

J. Grippo, Zhi-xin Xu, B. Brennan, 2013, British journal of clinical pharmacology.

The pharmacokinetics of peginterferon alfa‐2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C

C. Hagedorn, J. Grippo, T. Marbury, 2012, Alimentary pharmacology & therapeutics.

Effect of Ritonavir‐Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on the Pharmacokinetics of Methadone in Healthy Subjects Undergoing Methadone Maintenance Therapy

P. N. Morcos, Patrick F. Smith, B. Brennan, 2014, Pharmacotherapy.

Effect of age and gender on the pharmacokinetics of R667, a novel agent for the treatment of emphysema, in healthy volunteers.

S. Kolis, B. Brennan, Y. Chiu, 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.

J. Grippo, Zhi-xin Xu, B. Brennan, 2012, Clinical therapeutics.

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail

P. N. Morcos, Patrick F. Smith, Linda Chang, 2013, European Journal of Clinical Pharmacology.

Disease–Drug–Drug Interaction Assessments for Tocilizumab—A Monoclonal Antibody against Interleukin‐6 Receptor to Treat Patients with Rheumatoid Arthritis

Xiaoping Zhang, B. Brennan, 2013 .

The Effect of Food on the Pharmacokinetics of a Dual Angiotensin‐Converting Enzyme/Neutral Endopeptidase Inhibitor, M100240

J. Barrett, N. Martin, B. Brennan, 2004, Journal of clinical pharmacology.

Effect of Ritonavir‐Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on QTc Interval in Healthy Subjects: Results from a Thorough QT Study

P. N. Morcos, Patrick F. Smith, B. Brennan, 2013 .

Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis C.

E. Snoeck, Navita L. Mallalieu, B. Brennan, 2016, British journal of clinical pharmacology.

Ritonavir‐boosted danoprevir plus peginterferon alfa‐2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis

J. Kao, I. Sheen, T. Tanwandee, 2016, Journal of gastroenterology and hepatology.

Pharmacokinetics and Safety of Coadministered Oseltamivir and Rimantadine in Healthy Volunteers: An Open‐Label, Multiple‐Dose, Randomized, Crossover Study

B. Davies, B. Brennan, G. Cirrincione-Dall, 2012, Journal of clinical pharmacology.

Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a–Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders

R. Petric, E. Gane, D. Larrey, 2013, Antimicrobial Agents and Chemotherapy.

Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers

Patrick F. Smith, B. Brennan, S. Moreira, 2014, The Journal of pharmacy and pharmacology.

Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis

C. Stedman, T. Hassanein, E. Gane, 2016, Hepatology International.

1046 FIRST-IN-MAN DEMONSTRATION OF POTENT ANTIVIRAL ACTIVITY WITH A NUCLEOSIDE POLYMERASE (R7128) AND PROTEASE (R7227/ITMN-191) INHIBITOR COMBINATION IN HCV: SAFETY, PHARMACOKINETICS, AND VIROLOGIC RESULTS FROM INFORM-1

R. Elston, P. Angus, C. Stedman, 2009 .

Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir

P. Goelzer, C. Funk, P. N. Morcos, 2015, Clinical Pharmacokinetics.

Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible

Micaela B. Reddy, A. Connor, Philip Evans, 2011, Biopharmaceutics & drug disposition.

Pharmacokinetics of a Three-Way Drug Interaction Between Danoprevir, Ritonavir and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin

P. Goelzer, P. N. Morcos, Patrick F. Smith, 2013, Clinical Pharmacokinetics.

Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device

C. Bernaards, K. Beavers, E. Lawitz, 2011, Patient preference and adherence.

Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease.

N. Martin, B. Brennan, 2004, Journal of the American Pharmacists Association : JAPhA.

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.

B. Ploeger, N. Sharma, M. Fakih, 2023, EClinicalMedicine.

Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate

P. N. Morcos, P. F. Smith, B. Brennan, 2013, European Journal of Clinical Pharmacology.

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail

P. N. Morcos, Patrick F. Smith, Linda Chang, 2013, European Journal of Clinical Pharmacology.

Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).

P. Galle, A. El-Khoueiry, Ying A. Wang, 2021 .

1180 RITONAVIR SUBSTANTIALLY REDUCES REACTIVE METABOLITE FORMATION OF THE HCV PROTEASE INHIBITOR DANOPREVIR BOTH IN VITRO AND IN VIVO

T. Singer, P. Goelzer, P. N. Morcos, 2012 .

Effect of R667, a Novel Emphysema Agent, on the Pharmacokinetics of Midazolam in Healthy Men

B. Davies, C. Gooden, S. Kolis, 2006, Journal of clinical pharmacology.

Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible

A. Connor, Philip Evans, M. Reddy, 2011, Biopharmaceutics & drug disposition.

A grapefruit a day for patients infected with hepatitis C?

P. N. Morcos, Patrick F. Smith, B. Brennan, 2008, Hepatology.

Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment

C. Rayner, P. N. Morcos, N. Frey, 2015, Clinical pharmacology in drug development.